Obesity is a major global health issue. Most obese patients develop metabolic syndrome, a cluster of clinical features characterized by hypertension, insulin resistance and dyslipidemia this pre-diabetic condition has recognized as an independent risk factor for cardiovascular diseases, particularly hypertension, atherosclerosis and diabetic cardiomyopathy. MSC can differentiate into many mesenchymal cells as cardiomyocytes. The application of MSCs in the treatment of DC in recent years offers promising results. Stem cell therapy has emerged as a promising strategy for the treatment of dead myocardium, directly or indirectly, and seems to offer functional benefits to patients.Recently, a substantial number of clinical trials have proven that stem cell therapy is safe. Infusion of bone marrow-derived stem cells (BMCs) represents the greatest number of clinical studies for MI. This review highlights the use of mesenchymal stem cells in metabolic syndrome and diabetic cardiomyopathy
Introduction
Metabolic syndrome is regarded as a complex cluster of obesity-related complications, and, in recent years, this syndrome has become a global health problem [1] [2] [3] . Dyslipidemia, hypertension, and diabetes or glucose dysmetabolism are the major factors constituting metabolic syndrome, and these factors are interrelated and share underlying pathophysiological mechanisms [1] [2] [3] . Severe obesity predisposes individuals to metabolic syndrome and affected patients have an increased risk of cardiovascular disease and mortality [1] [2] [3] . Heart disease remains a major cause of worldwide morbidity and mortality. Despite advances in clinical and surgical care of cardiac patients, current therapies are able to treat symptoms, delay clinical deterioration, and increase survival but are not effective in repair induction in a diseased heart. This is the case of cardiomyopathy caused by metabolic diseases like diabetes. Therefore, a major effort is under way to develop therapies aiming at regenerating the myocardium or to stimulate endogenous repair programs [4] .Both types of DM increase the progression of atherosclerosis and the development of macrovascular complications, with clinical manifestations such as coronary artery disease ( CAD), peripheral artery disease (PAD), and stroke, and these patients have a two to four fold increased risk of fatal myocardial infarction (MI) [5] . Development of ventricular dysfunction in patients with DM in the absence of CAD, valvular heart disease or hypertension is defined as diabetic cardiomyopathy (DC) [6] . DC caused by hyperglycemia causes changes in the diabetic myocardium such as hypertrophy, apoptosis of cardiomyocytes, and abnormal myocardial matrix deposition. Specifically in DC, there are changes in the activity of matrix metalloproteases MMP-2 and MMP-9. Reduced MMP-2 activity results in increased collagen accumulation and increased activity of proapoptotic MMP-9 and subsequent cell apoptosis, capillary density reduction, and poor myocardial perfusion.
Other pathological consequences include microcirculatory defects, and interstitial fibrosis [7] . 
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